Global Oncology External Innovation Hub
As our priority area of research, Boston Biomedical is committed to propelling drug discovery in oncology. To help spark meaningful research in this space, our parent organization, Sumitomo Dainippon Pharma, made a significant investment to establish a Global Oncology External Innovation Hub in Cambridge, Mass., to enhance collaboration with those that share in our joint pursuit to fight cancer with science.
The External Innovation Hub, led by Mahmoud Mahmoudian, Ph.D., FRSC, is an integral part of our research partnerships to advance the discovery of novel therapeutics under the direction of David J. Bearss, Ph.D., Global Head of Research.
In December 2019, we entered into an alliance with three world-leading oncology centers of excellence—Columbia University, Harvard University and The Wistar Institute. Through this alliance we are supporting research endeavors dedicated to finding novel targets and platform technologies for the development of cancer drugs.
By leveraging each institution’s unique technologies and therapeutic insights to pursue specific research areas, we believe this agreement will bring us closer to filling unmet needs in oncology. More details on the alliance can be found in our press release.
Oncology Innovations Investment
In March 2020, Sumitomo Dainippon Pharma invested in the MPM Oncology Innovations Fund and made a donation to the Dana-Farber Innovations Research Fund. These two funds are a unique, first-of-its-kind, impact investing collaboration, which partners fundraising for biotech venture capital investing with philanthropic fundraising for cancer research.
Harnessing MPM Capital’s expertise in establishing and investing in life science companies, we believe this effort will enable efficiencies in the drug discovery process and the use of cutting-edge technologies in oncology. More details on the funds can be found in our press release.